Cloverleaf Bio Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$33M
- Investors
-
17
Cloverleaf Bio General Information
Description
Developer of a Ribonucleic Acid (RNA) therapeutics development platform designed to revolutionize cancer therapy and patient outcomes in oncology. The company's platform allows for direct inhibition of various enzymes necessary for cancer growth from a single therapeutic molecule, enabling engineered tRNA therapeutics to improve patient outcomes in oncology.
Contact Information
Website
www.cloverleafbio.comCorporate Office
- 101 College Street
- Suite 210
- New Haven, CT 06510
- United States
Corporate Office
- 101 College Street
- Suite 210
- New Haven, CT 06510
- United States
Cloverleaf Bio Timeline
Cloverleaf Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Seed Round | 08-Sep-2026 | $33M | Completed | Pre-Clinical Trials | ||
| 10. Grant | 23-Jun-2025 | Completed | Pre-Clinical Trials | |||
| 9. Accelerator/Incubator | 08-May-2025 | Completed | Pre-Clinical Trials | |||
| 8. Accelerator/Incubator | 01-May-2025 | Completed | Pre-Clinical Trials | |||
| 7. Accelerator/Incubator | 01-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 6. Early Stage VC | 30-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC | 22-Mar-2024 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | 30-Sep-2023 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 13-Jul-2023 | $50K | $50K | Completed | Pre-Clinical Trials | |
| 2. Grant | 09-Jun-2023 | $100K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Cloverleaf Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cloverleaf Bio Patents
Cloverleaf Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026055327-A2 | Rna-based inhibitors of trna modifying enzymes | Pending | 05-Sep-2024 | ||
| WO-2026055327-A3 | Rna-based inhibitors of trna modifying enzymes | Pending | 05-Sep-2024 |
Cloverleaf Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cloverleaf Bio Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 4BIO Capital | Venture Capital | Minority | ||
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority | ||
| Eli Lilly and Company Foundation | Limited Partner | Minority | ||
| National Cancer Institute | Government |
Cloverleaf Bio FAQs
-
When was Cloverleaf Bio founded?
Cloverleaf Bio was founded in 2023.
-
Where is Cloverleaf Bio headquartered?
Cloverleaf Bio is headquartered in New Haven, CT.
-
What is the size of Cloverleaf Bio?
Cloverleaf Bio has 4 total employees.
-
What industry is Cloverleaf Bio in?
Cloverleaf Bio’s primary industry is Drug Discovery.
-
Is Cloverleaf Bio a private or public company?
Cloverleaf Bio is a Private company.
-
What is Cloverleaf Bio’s current revenue?
The current revenue for Cloverleaf Bio is .
-
How much funding has Cloverleaf Bio raised over time?
Cloverleaf Bio has raised $34M.
-
Who are Cloverleaf Bio’s investors?
4BIO Capital, AbbVie Ventures, Boehringer Ingelheim Venture Fund, Eli Lilly and Company Foundation, and National Cancer Institute are 5 of 17 investors who have invested in Cloverleaf Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
